Long-term safety study of a MPS II treatment
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism, Skin clinical trials.
This study is for people with MPS II (Hunter syndrome) who have already completed a previous Denali study. It will test a drug called tividenofusp alfa (DNL310) over a longer period to see how safe it is and how well it works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have completed the previous MPS II study (DNLI-E-0002 or DNLI-E-0007).
- From study DNLI-E-0002: you must have finished at least the Week 49 visit and not stopped treatment early.
- From study DNLI-E-0007: you must have finished the full treatment period (96 weeks for some, 48 weeks for others).
- You cannot have other unstable medical conditions that would make participation unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is a follow-up study for people who already took JR-141 in an earlier trial for Hunter syndrome (MPS II). It checks how well the treatment works over the long term and monitors long-term safety.
This study follows people with MPS, a rare genetic condition, to learn more about the disease over time. If you have a confirmed MPS diagnosis, you may be able to join.
This program provides early access to an experimental enzyme therapy given directly into the brain for children with Sanfilippo syndrome type B, a genetic condition that affects the nervous system. The treatment aims to replace a missing enzyme to slow or stabilize symptoms.
This early-stage trial tests JR-446, a new treatment for MPS IIIB, a rare genetic disorder that affects the brain and body. The treatment is delivered directly into the fluid around the spinal cord and aims to slow or improve symptoms in young children.
This Phase 4 trial studies how safe, tolerable, and helpful ICV AX 250 is for people with MPS IIIB. It is for participants who already finished a prior AX 250 study and meet specific health and eligibility checks.
This trial looks at how safely givinostat works over a longer time in people with Duchenne muscular dystrophy (DMD). It mainly checks long-term side effects and tolerability, especially in a specific subgroup of muscle fat levels.
Hear when a new Mucopolysaccharidosis II trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.